Treatments for lupus nephritis: A systematic review and network metaanalysis

Journal of Rheumatology

Volumn 43, Issue 10, 2016, Pages 1801-1815

  Singh, Jasvinder A ^a   Hossain, Alomgir ^b   Kotb, Ahmed ^c   Oliveira, Ana ^d   Mudano, Amy S ^e   Grossman, Jennifer ^f   Winthrop, Kevin ^b   Wells, George A ^a  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF OREGON   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Lupus Nephritis; Metaanalysis; Network Metaanalysis; Systematic Review; Treatments

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

CANCER RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; END STAGE RENAL DISEASE; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION RISK; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; META ANALYSIS; REMISSION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 84989954667     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160041     Document Type: Review

References (104)

1. Alarcón GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP; PROFILE Study Group. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002;11:95-101.
2. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine 2006;85:147-56.
3. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-65.
4. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 2005;53:781-4.
5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine 2003;82:299-308.
6. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis 2006;65:1500-5.
7. Barr RG, Seliger S, Appel GB, Zuniga R, DAgati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-46.
8. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64:797-808.
9. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000;39:1383-9.
10. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.
11. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
12. Houssiau FA, DCruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-Term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
13. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012;12:CD002922.
14. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: A systematic review and network metaanalysis. J Rheumatol 2015;42:1392-400.
15. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: A network meta-Analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794.
16. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Sao Paulo Med J 2010;128:309-10.
17. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev 2009:CD007848.
18. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. [Internet. Accessed June 23, 2016.] Available from: effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-And-reports/?pageaction= displayProduct&productID=318
19. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). London: The Cochrane Collaboration; 2011.
20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med 2009;6:e1000097.
21. Singh JA, Noorbaloochi S, Tucker MD. Belimumab for systemic lupus erythematosus (protocol). [Internet. Accessed July 7, 2016.] Available from: onlinelibrary.wiley.com/doi/10.1002/14651858.CD010668/pdf
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). [Internet. Accessed June 23, 2016.] Available from: handbook.cochrane.org
24. Lumley T. Network meta-Analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
25. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-Analysis. JAMA 2003;289:2534-44.
26. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
27. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: generalised linear modelling framework for pairwise and network meta-Analysis of randomised controlled trials. [Internet. Accessed July 7, 2016.] Available from: www.nicedsu.org.uk/TSD2%20General%20meta%20analysis% 20corrected%2015April2014.pdf
28. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-Adjustment. [Internet. Accessed July 7, 2016.] Available from: www.nicedsu.org.uk/TSD3%20Heterogeneity. final%20report.08.05.12.pdf
29. Ohlssen D, Price KL, Xia HA, Hong H, Kerman J, Fu H, et al. Guidance on the implementation and reporting of a drug safety Bayesian network meta-Analysis. Pharm Stat 2014;13:55-70.
30. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009;28:1861-81.
31. Turner RM, Thompson SG, Spiegelhalter DJ. Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials. Clin Trials 2005;2:108-18.
32. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual. Version 1.4. [Internet. Accessed July 7, 2016.] Available from: www.mrc-bsu.cam.ac.uk/wp-content/uploads/manual14.pdf
33. Ades AE, Welton NJ, Caldwell D, Price M, Goubar A, Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy 2008;13 Suppl 3:12-22.
34. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. [Internet. Accessed July 7, 2016.] Available from: www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf
35. Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901-11.
36. Carette S, Klippel JH, Decker JL, Austin HA, Plotz PH, Steinberg AD, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-Term follow-up. Ann Intern Med 1983; 99:1-8.
37. Steinberg AD, Steinberg SC. Long-Term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
38. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin Proc 1976; 51:484-94.
39. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991;114:924-9.
40. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, et al. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
41. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002; 115:705-9.
42. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007;16:707-12.
43. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology 2010; 49:128-40.
44. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
45. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al; China Leflunomide Lupus Nephritis Study Group. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus 2008;17:638-44.
46. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
47. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
48. Balletta M, Sabella D, Magri P, Sepe V, Stanziale P, Di Luccio R, et al. Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992;99:129-30.
49. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-10.
50. Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 1982;101:137-41.
51. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
52. Cade R, Spooner G, Schlein E, Pickering M, DeQuesada A, Holcomb A, et al. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 1973;10:37-56.
53. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
54. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-Term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44.
55. Clark WF, Lindsay RM, Cattran DC, Chodirker WB, Barnes CC, Linton AL. Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A pilot study. Can Med Assoc J 1981;125:171-4.
56. Clark WF, Cattran DC, Balfe JW, Williams W, Lindsay RM, Linton AL. Chronic plasma exchange in systemic lupus erythematosus nephritis. Proc Eur Dial Transplant Assoc 1983;20:629-35.
57. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, ONan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
58. Zavada J, Pesickova S, Rysava R, Olejarova M, Horák P, Hrncir Z, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study. Lupus 2010;19:1281-9.
59. Derksen RH, Hené RJ, Kallenberg CG, Valentijn RM, Kater L. Prospective multicentre trial on the short-Term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 1988;33:168-77.
60. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 1974;17:573-81.
61. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-5.
62. Doria A, Piccoli A, Vesco P, Vaccaro E, Marson P, De Silvestro G, et al. Therapy of lupus nephritis. A two-year prospective study. Ann Med Interne 1994;145:307-11.
63. Dyadyk A, Vasilenko I, Bagriy A, Dyadyk O, Yarovaya N, Roschin Y, et al. Azathioprine and cyclophosphamide in treatment of patients with diffuse proliferative lupus nephritis-A randomized controlled study [abstract]. Nephrol Dial Transplant 2001;16:A57.
64. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 2010;14:214-21.
65. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998;37:217-21.
66. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
67. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
68. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al; Dutch Working Party on Systemic Lupus Erythematosus. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42.
69. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med 1975;83:597-605.
70. Hong R, Haijin Y, Xianglin W, Cuilan H, Nan C. Preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis [abstract]. Nephrol Dial Transplant 2007;22 Suppl 6:vi276.
71. Houssiau FA, Vasconcelos C, DCruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
72. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-9.
73. Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology 2009;48:892-8.
74. Li X, Ren H, Zhang W, Xu Y, Shen P, Zhang Q, et al. Induction therapies for proliferative lupus nephritis: mycophenolate mofetil, tacrolimus and intravenous cyclophosphamide [abstract]. J Am Soc Nephrol 2009;20:391A.
75. Lui SF, Cheng IK, Tong KL, Li CS, Wong KC, Chang DT, et al. Treatment of type IV lupus nephritis (LN)-comparison of 2 triple therapy regimens: cyclosporin a (CSA), prednisolone (PRED), azathioprine (AZA) vs. oral cyclophosphamide (POCP), prednisolone, azathioprine [abstract]. Nephrology 1997;3 Suppl 1:S476.
76. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
77. Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al Suwaida A, Alam A, et al. Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: A long-Term randomized controlled trial. Saudi J Kidney Dis Transpl 2011;22:935-40.
78. Mok CC, Ying SK, Tong KH, Siu YP, To CH, Yim CW, et al. Mycophenolate mofetil versus tacrolimus for active lupus nephritis: An extended observation of a randomized controlled trial [abstract]. Ann Rheum Dis 2009;68 Suppl 3:246.
79. Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32.
80. Mulic-Bacic S, Antic D, Krizic M, Hajdarovic A, Mulic E. Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis [abstract]. Ann Rheum Dis 2008;67 Suppl II:349.
81. Jayne DR, Zeher M. Enteric-coated mycophenolate sodium (ED-MPS) for the treatment of lupus nephritis-MyLupus study [abstract]. J Am Soc Nephrol 2010;21:626A.
82. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10.
83. Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: An Egyptian experience. Int Urol Nephrol 2009;41:153-61.
84. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-12.
85. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: A controlled trial. Ann Intern Med 1971;75:165-71.
86. Sundel RP, Lisk L. Mycophenolate mofetil compared with intravenous cyclophosphamide as induction treatment for pediatric lupus nephritis: A randomized trial [abstract]. [Internet. Accessed July 7, 2016.] Available from: Acr.confex.com/acr/2008/webprogram/Paper2748.html
87. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998;13:163-6.
88. Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004;63:525-9.
89. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-72.
90. Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology 2012;17:352-7.
91. Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C, et al; MAINTAIN Nephritis Trial Group. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012;27:1924-30.
92. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: A multicenter randomized clinical trial. Lupus 2012;21:944-52.
93. Arends S, Grootscholten C, Derksen RH, Berger SP, de Sevaux RG, Voskuyl AE, et al; Dutch Working Party on systemic lupus erythematosus. Long-Term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2012;71:966-73.
94. Sundel R, Solomons N, Lisk L, Aspreva Lupus Management Study (ALMS) Group. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 2012;21:1433-43.
95. Walsh M, Solomons N, Lisk L, Jayne DR. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: A subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013;61:710-5.
96. Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: A prospective randomized trial. Arthritis Rheum 2010;62:1487-93.
97. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011;20:1484-93.
98. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
99. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 2013;22:238-44.
100. Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. Herpes zoster vaccination in SLE: A pilot study of immunogenicity. J Rheumatol 2013;40:1875-80.
101. Marmont AM, Bacigalupo A, Gualandi F, Bregante S, van Lint MT, Geroldi S. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA). Bone Marrow Transplant 2014;49:982-3.
102. Merck. Zostavax: highlights of prescribing information. [Internet. Accessed June 23, 2016.] Available from: www.merck.com/product/usa/pi-circulars/z/zostavax/zostavax-pi2.pdf
103. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: A systematic review and network metaanalysis. J Rheumatol 2014;41:1998-2007.
104. Song F, Clark A, Bachmann MO, Maas J. Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. BMC Med Res Methodol 2012;12:138.